Patents Issued in December 4, 2018
-
Patent number: 10143737Abstract: The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel methods to select HIV infected patients with improved responses to HIV-specific vaccine peptides.Type: GrantFiled: January 27, 2015Date of Patent: December 4, 2018Assignee: BIONOR PHARMA ASAInventors: Anker Lundemose, Mats Ökvist, Arnt Ove Hovden, Maja Sommerfelt Grønvold
-
Patent number: 10143738Abstract: The invention pertains to a vaccine for use in protecting a pig against an infection with porcine epidemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, by administration of a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting a pig against an infection with porcine epidemic diarrhea virus.Type: GrantFiled: September 11, 2015Date of Patent: December 4, 2018Assignees: Intervet Inc., Universiteit Utrecht Holding B.V.Inventors: Erwin Born, van den, Berend Jan Bosch, Peter Rottier
-
Patent number: 10143739Abstract: Isolated porcine epidemic diarrhea virus (PEDV) deposited under ATCC Accession No. PTA-121847, and attenuated strains generated by serial passage in culture of the deposited strain. Immunogenic compositions for reducing the incidence or severity of clinical symptoms from PEDV infection, and methods of making and using the same.Type: GrantFiled: February 3, 2016Date of Patent: December 4, 2018Assignee: KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Kyeong-Ok Chang, Yunjeong Kim, Richard A. Hesse
-
Patent number: 10143740Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.Type: GrantFiled: May 5, 2014Date of Patent: December 4, 2018Assignee: Oregon Health and Science UniversityInventors: Mark K. Slifka, Shirley Villadiego, Erika Hammarlund, Paul Yoshihara
-
Patent number: 10143741Abstract: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.Type: GrantFiled: April 14, 2014Date of Patent: December 4, 2018Assignee: Sanofi Pasteur SAInventors: Alain Bouckenooghe, Remi Forrat, Denis Crevat
-
Patent number: 10143742Abstract: Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.Type: GrantFiled: July 29, 2016Date of Patent: December 4, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Kari C. Nadeau
-
Patent number: 10143743Abstract: The present invention provides compositions and methods for the secretion and the translocation of a compound of interest by a bacterial minicell. In certain embodiments, the invention provides a bacterial minicell comprising at least one component of the type III secretion system (T3SS), which provides a safe and efficient system for secretion and translocation. In one embodiment, the invention allows for the delivery of an antigen to a cell or subject in order to induce an immune response.Type: GrantFiled: October 31, 2014Date of Patent: December 4, 2018Assignee: YALE UNIVERSITYInventors: Jorge Galan, Heather Carleton
-
Patent number: 10143744Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.Type: GrantFiled: January 26, 2016Date of Patent: December 4, 2018Assignees: Avanti Polar Lipids, Inc, AC Immune SAInventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
-
Patent number: 10143745Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.Type: GrantFiled: November 17, 2016Date of Patent: December 4, 2018Assignee: GlacoSmithKline Biologicals, S.A.Inventor: Pierre Vandepapeliere
-
Patent number: 10143746Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: March 1, 2017Date of Patent: December 4, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola
-
Patent number: 10143747Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.Type: GrantFiled: September 22, 2011Date of Patent: December 4, 2018Assignee: IMBA—INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBHInventors: Josef Penninger, Daniel Schramek
-
Patent number: 10143748Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: GrantFiled: March 15, 2013Date of Patent: December 4, 2018Assignee: Aptevo Research and Development LLCInventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
-
Patent number: 10143749Abstract: There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.Type: GrantFiled: March 28, 2014Date of Patent: December 4, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Mi Young Cho, Powei Lin, Seung Hyun Lee, Kwang Ho Cheong, Young Jun Koh, Christina Yi, Jae Woong Hwang
-
Patent number: 10143750Abstract: The present invention relates to a method for the treatment of cancer in a subject which comprises the steps of: (i) administering electroporation to a tumour in the subject; and (ii) administering a T or B-cell activating agent to the subject, wherein step (i) and (ii) may be performed in either order.Type: GrantFiled: May 8, 2015Date of Patent: December 4, 2018Assignee: University College CorkInventors: Declan Soden, Patrick Forde, Morgan O'Brien
-
Patent number: 10143751Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.Type: GrantFiled: October 8, 2015Date of Patent: December 4, 2018Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Gregor Medinger, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 10143752Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: GrantFiled: July 20, 2016Date of Patent: December 4, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Patent number: 10143753Abstract: The invention generally relates to synthetic mimics of cell penetrating peptides. More particularly, the invention relates to certain novel monomers, oligomers and polymers (e.g., co-polymers) that are useful for the preparation of synthetic mimics of cell penetrating peptides, their compositions, preparations and use.Type: GrantFiled: August 22, 2017Date of Patent: December 4, 2018Assignee: University of MassachusettsInventors: Gregory N. Tew, Gregory J. Gabriel, Abhigyan Som, Arife Ozgul Tezgel
-
Patent number: 10143754Abstract: A method for treating type 1 and type 2 diabetes by administering an oral pharmaceutical formulation which comprises of insulin or its analogs amalgamated with suitable encapsulating agents and pharmaceutical excipients. The encapsulated pharmaceutical oral formulation protects insulin or its analogs from harsh milieu of the gastrointestinal tract and facilitates efficient delivery of insulin at targeted sites with sustained hypoglycemic activity.Type: GrantFiled: August 7, 2012Date of Patent: December 4, 2018Assignee: TRANSGENE BIOTEK LIMITEDInventors: Koteswara Rao Kollipara, Gregory John Russell Jones
-
Patent number: 10143755Abstract: The present disclosure relates to anhydrous hydrogels useful as mucoadhesive (oral compositions) or as topical agents and may be used to deliver an active agent such as active pharmaceutical agents (API's), coagulants, fragrances, flavors, and other actives and excipients.Type: GrantFiled: December 8, 2017Date of Patent: December 4, 2018Assignee: Acupac Packaging Inc.Inventors: John Borja, Stephanie Sharon Hayano
-
Patent number: 10143756Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6-8, alternatively 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme disclosed herein to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: GrantFiled: January 29, 2018Date of Patent: December 4, 2018Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Patent number: 10143757Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.Type: GrantFiled: November 17, 2017Date of Patent: December 4, 2018Assignee: Sanofi Pasteur Inc.Inventor: Robert P. Ryall
-
Patent number: 10143758Abstract: Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: March 13, 2013Date of Patent: December 4, 2018Assignee: Translate Bio, Inc.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
-
Patent number: 10143759Abstract: A method of treating cancerous tumors is presented herein. The method includes injecting an effective dose of a plasmid encoded for IL-12, B7-1 or IL-15 into a cancerous tumor and subsequently administering at least one high voltage, short duration pulse to the tumor. The electroporation pulses may be administered at at least 700V/cm for a duration of less than 1 millisecond. The intratumor treatments with electroporation may be administered in at least a two-treatment protocol with the time between treatments being about 7 days. The intratumor treatments with electroporation may be administered in a three-treatment protocol with a time of four days between the first and second treatments and a time of three days between the second and third treatments. It was found that the intratumor treatments using electroporation not only resulted in tumor regression but also induced an immune memory response which prevented the formation of new tumors.Type: GrantFiled: April 3, 2017Date of Patent: December 4, 2018Assignee: University of South FloridaInventors: Richard Heller, Kenneth E. Ugen
-
Patent number: 10143760Abstract: Described herein are constructs used for liver-specific expression of a transgene.Type: GrantFiled: July 13, 2016Date of Patent: December 4, 2018Assignee: Sangamo Therapeutics, Inc.Inventors: Brigit E. Riley, Gary K. Lee
-
Patent number: 10143761Abstract: A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.Type: GrantFiled: June 18, 2013Date of Patent: December 4, 2018Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Hideki Miyake, Tomoko Oda
-
Patent number: 10143762Abstract: Provided is an articular cartilage imaging composition which can clearly distinguishably visualize a normal site and an abnormal site, i.e., a degenerative site, in articular cartilage. The articular cartilage imaging composition contains a positively charged molecule, which is labeled with a labeling molecule.Type: GrantFiled: December 8, 2014Date of Patent: December 4, 2018Assignee: Mercury Assel Management Co., Ltd.Inventors: Shuichi Mizuno, Nobuaki Kawaguchi, Akihiro Tsuchiya, Yoshinobu Manome
-
Patent number: 10143763Abstract: Disclosed herein are an apparatus, method and system for storing perishable items that degrade in the presence of oxygen and/or humidity and that are frequently accessed by a consumer. The apparatus comprises an openable insulated vessel with precisely controlled internal temperature and humidity, which becomes airtight when closed, and a corona ozone generator with an oxygen gas feed tank and fan within the insulated airtight enclosure, which converts ambient oxygen trapped within the airtight enclosure into ozone by circulating the enclosed volume of air through the corona ozone generator after the vessel is opened and then closed. Also disclosed is a refrigerated embodiment of the apparatus, which may be self-contained and transportable. The apparatus is network connected to allow for remote control and monitoring and sends alerts to web applications or mobile applications when monitored parameters substantially vary from their settings.Type: GrantFiled: September 13, 2017Date of Patent: December 4, 2018Inventors: Alfonso Campalans, Alexander Gray
-
Patent number: 10143764Abstract: A freshening composition is provided. The composition includes at least one particle, and an aqueous carrier. The composition includes a polysaccharide system having a first polysaccharide and a second polysaccharide. The first polysaccharide is xanthan gum and the second polysaccharide is selected from the group consisting of konjac gum, locust bean gum, and combinations thereof. The composition may include an unencapsulated perfume.Type: GrantFiled: July 27, 2017Date of Patent: December 4, 2018Assignee: The Procter & Gamble CompanyInventors: Matthew Lawrence Lynch, Carla Jean Colina, Steven Anthony Horenziak, Brandon Philip Illie, Yonas Gizaw, Yiping Sun
-
Patent number: 10143765Abstract: Provided are: a deodorizer that has high VOC-adsorbing performance and can exhibit deodorizing properties even in a case in which the deodorizer is kneaded into resin, a deodorizing processed product produced by using the deodorizer, and a method for producing the deodorizer. The deodorizer of the present invention is characterized by including a zeolite represented by the following Formula [1], in which the zeolite is obtained by producing a zeolite and then heating the produced zeolite at a temperature of from 120° C. to 250° C.: xNa2O.Al2O3.ySiO2.zH2O [1]. In Formula [1], x represents a positive number of from 0.5 to 5.0, y represents a positive number of from 80 to 150, and z represents a positive number of from 1 to 20.Type: GrantFiled: October 5, 2015Date of Patent: December 4, 2018Assignee: TOAGOSEI CO., LTD.Inventors: Kentarou Miyamura, Koji Sugiura
-
Patent number: 10143766Abstract: A volatile composition dispenser comprises a volatile composition container comprising at least one volatile composition therein. A rupture element is positioned proximate to the volatile composition container. The volatile composition container comprises a cam comprising a camming surface. The camming surface is configured to move at least a portion of the rupture element toward the volatile composition container to puncture the volatile composition container and release at least a portion of the volatile composition from the volatile composition container such that the portion of the volatile composition evaporates and exits the volatile composition dispenser.Type: GrantFiled: April 15, 2010Date of Patent: December 4, 2018Assignee: The Procter & Gamble CompanyInventors: Dana Paul Gruenbacher, Bryan Gabriel Comstock, James Douglas Still, Rainer Bernhard Teufel, Richard Lee Lane, Walter Sordo, Danilo Rossi
-
Patent number: 10143767Abstract: An appliance for delivering agent. The agent-delivery appliance includes an agent-releasing mechanism, an air-moving device that generates a flow of air moving from upstream to downstream, and at least one filter. The agent-releasing mechanism includes a chamber configured to release agent into the flow of air generated by the air-moving device. The chamber includes multiple openings, one of which is configured to provide air loaded with agent from the chamber to a first location within the flow of air generated by the air-moving device. At least one filter is located upstream from the first location within the flow of air generated by the air-moving device.Type: GrantFiled: June 12, 2014Date of Patent: December 4, 2018Assignee: Helen of Troy LimitedInventors: John Franks, Rich Thrush
-
Patent number: 10143768Abstract: An atomiser system includes a fragrance cartridge and a docking housing in which the fragrance cartridge is installed. The fragrance cartridge includes a bottle for holding a liquid fragrance therein; a wick extending down into the bottle; a piezo disc for atomising the liquid fragrance received from the wick; and an adjustable cap by which a user activates the cartridge, bringing the liquid fragrance into contact with a certain portion of the wick.Type: GrantFiled: January 19, 2017Date of Patent: December 4, 2018Assignee: AIR AROMA RESEARCH PTY LTDInventors: Johan Van Roemburg, Derk Reilink, Petrus Henricus Aloysius Nicolaus Kuhn
-
Patent number: 10143769Abstract: A storage apparatus according to an embodiment may include a body having a storage space of storage products and an air purifying module coupled to the body. The air purifying module may include a light emitting diode part disposed along a passage of air to provide ultraviolet light, and a filter part disposed adjacent to the light emitting diode part.Type: GrantFiled: July 29, 2014Date of Patent: December 4, 2018Assignee: SEOUL VIOSYS CO., LTD.Inventors: Jung Yeol Park, Young Hwan Son, Seong Min Lee, Jae Seon Yi, Jong Hyun Koo, Sang Hee Cho, Ju Won Yoo, Sung Lim Cho, Jong Rack Kim
-
Patent number: 10143770Abstract: The present invention relates to a photocatalytic apparatus and a heating, ventilating, and air conditioning (HVAC) equipment for a vehicle comprising the same and, more specifically, to a photocatalytic apparatus and HVAC equipment for a vehicle comprising the same, wherein the photocatalytic apparatus may sterilize and deodorize an evaporator in addition to purifying air introduced into an HVAC case and may continuously maintain sterilization and deodorization functions by efficiently radiating heat generated from the photocatalytic apparatus.Type: GrantFiled: March 22, 2016Date of Patent: December 4, 2018Assignee: HANON SYSTEMSInventors: Jae Ho Kim, Ki Hong Kim, Ji-Yong Park, Tae Yong Park, Yong Jun Jee
-
Patent number: 10143771Abstract: A wound dressing material may include a polymeric substrate, a silver salt, and a dyestuff to photostabilize the silver salt. The substrate may include collagen and/or oxidized regenerated cellulose complexed to Ag+, and the dyestuff may, for example, be an aniline or acridine dye. Also disclosed are methods of making such materials, and wound dressings that include such materials.Type: GrantFiled: January 15, 2015Date of Patent: December 4, 2018Assignee: KCI USA, Inc.Inventors: Deborah Addison, David Greenhalgh, Breda Mary Cullen
-
Patent number: 10143772Abstract: A system for managing female incontinence includes a body of biocompatible material configured to fit between the labia minora and the vestibule floor, the body having a surface configured to occlude the urethral meatus, an adhesive carried on at least a first portion of the surface and configured to provide a sealing engagement between the body and the urethral meatus, and a substance carried by at least one of the body and the adhesive and configured for controlling the odor of the general vaginal-urethral area of a female.Type: GrantFiled: September 15, 2017Date of Patent: December 4, 2018Assignee: SOFT HEALTH TECHNOLOGIES, LLCInventors: Thomas J. Berryman, John M. Taylor
-
Patent number: 10143773Abstract: A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water.Type: GrantFiled: October 16, 2015Date of Patent: December 4, 2018Assignee: Heraeus Medical GmbHInventor: Sebastian Vogt
-
Patent number: 10143774Abstract: The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralization of a tissue in osseous site, as well as in non-osseous site, in the absence of stem cells or growth factors.Type: GrantFiled: July 24, 2017Date of Patent: December 4, 2018Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE BORDEAUX II VICTOR SEGALEN, UNIVERSITÉ PARIS DIDEROT—PARIS 7Inventors: Joelle Amedee, Didier Letourneur, Catherine Le Visage, Sidi Mohammed Derkaoui, Jean-Christophe Fricain, Sylvain Catros
-
Patent number: 10143775Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.Type: GrantFiled: October 21, 2016Date of Patent: December 4, 2018Assignee: Globus Medical, Inc.Inventor: Vipin Kunjachan
-
Patent number: 10143776Abstract: Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved.Type: GrantFiled: June 30, 2011Date of Patent: December 4, 2018Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Sharon Gerecht, Guoming Sun, Yu-I Shen
-
Patent number: 10143777Abstract: Described herein are fenestrated placental tissue allografts, methods for using the same for treating wounds that produce an exudate and to promote the healing process, and apparatus and kits for making the same that minimize or eliminate cross-contamination with placental tissue from other placental donors.Type: GrantFiled: November 16, 2015Date of Patent: December 4, 2018Assignee: MiMedx Group, Inc.Inventors: Rick LeVaughn, Nicole Zabek
-
Patent number: 10143778Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.Type: GrantFiled: December 21, 2016Date of Patent: December 4, 2018Assignee: CORMATRIX CARDIOVASCULAR, INCInventor: Robert G Matheny
-
Patent number: 10143779Abstract: A method of inhibiting thickening of vascular intima by providing a medical device having an expandable member having a drug coating layer which has a crystalline morphological form including a plurality of crystal particles of a water-insoluble drug regularly arranged and uniformly sized on the surface of the medical device, inserting the medical device in peripheral blood vessels, expanding the expandable member, pressing the drug coating layer to a blood vessel wall such that at least part of the plurality of crystals are transferred to the blood vessel wall, and deflating the expandable member such that a vascular intima thickening is inhibited uniformly in an entire treated lesion of stenosis to uniformly cause patency of the lesion.Type: GrantFiled: August 12, 2014Date of Patent: December 4, 2018Assignee: TERUMO KABUSHIKI KAISHAInventors: Keiko Yamashita, Shigenori Nozawa, Katsumi Morimoto
-
Patent number: 10143780Abstract: Devices, methods and compositions for treating cardiovascular disorders are configured for sustained-release of leptin antagonist into a blood vessel in order to downregulate an expression or activity of leptin in a cardiovascular tissue that is affected by a disorder.Type: GrantFiled: January 19, 2016Date of Patent: December 4, 2018Inventor: Jacob Schneiderman
-
Patent number: 10143781Abstract: A chest drainage container for withdrawing and collecting certain body fluids from within a patient's chest cavity includes means for tolerating the container being accidentally tipped over. To provide such means, some example containers disclosed in this patent merely involve modifying the plastic injection mold of an existing chest drainage container. In some examples, certain partitions and vents are integrally formed in the container's main body. In the event of a tip-over occurrence, the partitions trap collected fluid within their appropriate collection chambers to help prevent inter-chamber mixing of fluid. During normal operation, the vents enable a pocket of otherwise trapped air to escape from within the enclosed collection chambers as incoming body fluid displaces the air. In some examples, under certain conditions, the vent releases gaseous fluid at a volumetric flow that is about 30 times greater than what the vent releases of liquid fluid during a tip-over event.Type: GrantFiled: August 23, 2014Date of Patent: December 4, 2018Inventors: Ashia M. Pollen, Robert J. Harter
-
Patent number: 10143782Abstract: A blood collection canister assembly enables a user to collect and transfer blood and includes liner and lid assemblies. The liner assembly is formed from a flexible liner material and defines an inner liner space. The lid assembly includes a primary lid portion attached to an upper mouth of the liner assembly and includes a series of ports. The series of ports may include a vacuum port, a patient port, a transfer port, and an additive port. The vacuum port is communicable with a vacuum line for directing blood transfer from a patient via the blood collection canister assembly. The patient port receives directed blood transfer from the patient, and the transfer port transfers collected blood to a separate reservoir for further processing. The blood collection canister assembly is usable in either an upright, first configuration for collecting and transferring blood or an inverted, second configuration for transferring collected blood.Type: GrantFiled: June 30, 2016Date of Patent: December 4, 2018Assignee: ECOMED SOLUTIONS, LLCInventors: David A. Yurek, James R. Trickett
-
Patent number: 10143783Abstract: Some embodiments comprise a pump assembly for reduced pressure wound therapy, comprising a housing, a flow pathway through the pump, one or more valves in communication with the flow pathway, a pump supported within or by the housing, and a one-way flow valve in fluid communication with the pump. The pump assembly can have a pressure sensor in communication with the flow pathway through the pump, and at least one switch or button supported by the housing, the at least one switch or button being accessible to a user and being in communication with the controller. The one-way flow valve can be configured to substantially prevent a flow of gas through the one-way flow valve in a direction of flow away from the pump. The pump assembly can have a controller supported within or by the housing, the controller being configured to control an operation of the pump.Type: GrantFiled: November 10, 2014Date of Patent: December 4, 2018Assignee: Smith & Nephew PLCInventors: Gordon Campbell Adie, Julie Allen, Victoria Beadle, Sarah Jenny Collinson, Christopher John Fryer, Edward Yerbury Hartwell, Elizabeth Anne Fyfe Jennings, Derek Nicolini, Yannick Louis Peron
-
Patent number: 10143784Abstract: Some embodiments are directed to a system 10 for the application of topical negative pressure therapy to a site 18 on the body of a mammal. Some embodiments of the system 10 comprise a piston 22 and cylinder 24 device 12 having a self-contained power source for the generation of a reduced pressure and for aspirating the site 18. Some embodiments of the system 10 comprise a dressing 14 sealably surrounding the site 18 that can be operably connected to the device 12 by a conduit means 16 to apply the reduced pressure to the site 18.Type: GrantFiled: December 1, 2016Date of Patent: December 4, 2018Assignee: T.J. Smith & Nephew LimitedInventors: Edward William Walton, George Russell Walton
-
Patent number: 10143785Abstract: Embodiments of negative pressure wound therapy systems and methods for operating the systems are disclosed. In some embodiments, a system includes a negative pressure source, a wound dressing configured to be positioned over a wound, and optionally a canister configured to store fluid aspirated from the wound. The negative pressure source, wound dressing, and canister (when present) can be fluidically connected to facilitate delivery of negative pressure to the wound. The system can be configured to automatically detect whether the canister is positioned in the fluid flow path between the negative pressure source and the dressing while negative pressure source provides negative pressure to the wound dressing. Operation of the system can be adjusted based on whether presence of the canister has been detected. For example, a value of an operational parameter can be set to indicate that the canister is present.Type: GrantFiled: February 13, 2018Date of Patent: December 4, 2018Assignee: Smith & Nephew, Inc.Inventors: Eric Edward Adams, Kevin Bendele, Aaron Michael Husz, David Edward Lee, Felix Clarence Quintanar, Lee Michael Rush, David Ronald Upton, William Jacob Ward
-
Patent number: 10143786Abstract: A breast pump system includes a solenoid valve and a power source. The power source is arranged to supply electrical power to the solenoid valve so as enable the solenoid valve to move between first and second positions. The breast pump system also includes a controller configured to detect a change in inductance of the solenoid valve that is indicative of the solenoid valve moving from first to second position and a control action in which the vacuum pump is stopped.Type: GrantFiled: July 31, 2017Date of Patent: December 4, 2018Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Arnold Aalders, Hassan El Barakat, Theodorus Johannes Adrianus Maria Den Bekker, Cornelis Johannes Janson